APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:1000 |
| 1:250 |
| 1:20 |
Not tested in other applications.
Calculated MW
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA, 50% Glycerol
Preservative
0.05% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human VEGFR2 that contains tyrosines 1054 and 1059. The sequence is conserved among multiple species including mouse and rat.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
kinase insert domain receptor , CD309 , FLK1 , VEGFR , VEGFR2
Cellular Localization
Cell junction,Endoplasmic reticulum,Cytoplasm,Nucleus,Cytoplasmic vesicle
Background
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]
Database
Research Area
DATA IMAGES
|
GTX25473 WB Image
WB analysis of whole cell extracts (30 μg lysate) of HUVEC (Lane 1), treated with 25ng/mL VEGF for 5 minutes (lane 2), MDA-MB-231 (lane 3), and MCF7 (Lane 4) using GTX25473 VEGF Receptor 2 (phospho Tyr1054/Tyr1059) antibody.
Dilution : 1:1000
|
|
|
GTX25473 WB Image
WB analysis of PAE cells transfected with a chimeric receptor unstimulated (Lane 1, 2) or stimulated with 40ng/mL CSF-1 for 10 minutes (Lane 3-8) using GTX25473 VEGF Receptor 2 (phospho Tyr1054/Tyr1059) antibody.
|
|
|
GTX25473 ICC/IF Image
ICC/IF analysis of HUVEC cell treated with 100ng of VEGF for 30 minutes using GTX25473 VEGF Receptor 2 (phospho Tyr1054/Tyr1059) antibody. Panel e is untreated cell with no signal. Panel f represents control cells with no primary antibody to assess background.
Green : Primary antibody
Blue : Nuclei
Red : Actin
Fixation : 4% paraformaldehyde
Permeabilization : 0.1% Triton X-100 for 10 minutes
|
REFERENCE
There are currently no references for VEGF Receptor 2 (phospho Tyr1054/Tyr1059) antibody (GTX25473). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for VEGF Receptor 2 (phospho Tyr1054/Tyr1059) antibody (GTX25473). Be the first to share your experience with this product.
